Parathormone levels add prognostic ability to N‐terminal pro‐brain natriuretic peptide in stable coronary patients
暂无分享,去创建一个
J. Egido | I. Mahíllo-Fernández | L. Blanco-Colio | J. Martín-Ventura | E. González-Parra | Ó. Lorenzo | Luis Alonso-Pulpón | L. López Bescós | J. Tuñón | Á. Aceña | A. Pello | C. Cristóbal | N. Tarín | A. Huelmos | J. Alonso | M. González-Casaus | M. López-Castillo | J. Martínez-Milla | C. Gutiérrez-Landaluce | Ó. González-Lorenzo | Juan Martínez-Milla | Juan Martinez-milla | Nieves Tarín | Carlos Gutiérrez-Landaluce
[1] M. Szklo,et al. Impact of race on the association of mineral metabolism with heart failure: the Multi-Ethnic Study of Atherosclerosis. , 2019, The Journal of clinical endocrinology and metabolism.
[2] J. Manson,et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease , 2019, The New England journal of medicine.
[3] F. Rodríguez‐Artalejo,et al. Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate , 2016, Journal of Bone and Mineral Metabolism.
[4] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[5] S. Plein,et al. Effects of Vitamin D on Cardiac Function in Patients With Chronic HF , 2016, Journal of the American College of Cardiology.
[6] M. M. Joosten,et al. Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study , 2016, ESC heart failure.
[7] Y. Alsancak,et al. Association between parathyroid hormone levels and the extensiveness of coronary artery disease , 2016, Anatolian journal of cardiology.
[8] Bo Yang,et al. Parathyroid hormone, cardiovascular and all-cause mortality: A meta-analysis. , 2016, Clinica chimica acta; international journal of clinical chemistry.
[9] W. März,et al. Soluble klotho and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. , 2015, Atherosclerosis.
[10] H. Malluche,et al. High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis. , 2015, Journal of the American Society of Nephrology : JASN.
[11] B. Kestenbaum,et al. Serum Parathyroid Hormone and 25‐Hydroxyvitamin D Concentrations and Risk of Incident Heart Failure: The Multi‐Ethnic Study of Atherosclerosis , 2014, Journal of the American Heart Association.
[12] P. Whincup,et al. Elevated Parathyroid Hormone, But Not Vitamin D Deficiency, Is Associated With Increased Risk of Heart Failure in Older Men With and Without Cardiovascular Disease , 2014, Circulation. Heart failure.
[13] J. Pankow,et al. Parathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study. , 2014, American heart journal.
[14] D. Fliser,et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[15] F. Rodríguez‐Artalejo,et al. Coexistence of Low Vitamin D and High Fibroblast Growth Factor-23 Plasma Levels Predicts an Adverse Outcome in Patients with Coronary Artery Disease , 2014, PloS one.
[16] J. Egido,et al. Parathormone levels are independently associated with the presence of left ventricular hypertrophy in patients with coronary artery disease , 2015, The journal of nutrition, health & aging.
[17] F. Rodríguez‐Artalejo,et al. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. , 2014, The American journal of cardiology.
[18] M. Visser,et al. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. , 2013, American heart journal.
[19] A. Ortiz,et al. Vitamin D receptor activation and cardiovascular disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] B. Nordestgaard,et al. 25-Hydroxyvitamin D Levels and Risk of Ischemic Heart Disease, Myocardial Infarction, and Early Death: Population-Based Study and Meta-Analyses of 18 and 17 Studies , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[21] M. Pelizzo,et al. Coronary Microvascular Dysfunction Induced by Primary Hyperparathyroidism is Restored After Parathyroidectomy , 2012, Circulation.
[22] N. Fujii,et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[23] S. Solomon,et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. , 2012, JAMA.
[24] A. Go,et al. FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.
[25] B. Kestenbaum,et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. , 2011, Journal of the American College of Cardiology.
[26] B. Horne,et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? , 2011, American heart journal.
[27] A. Hayen,et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. , 2011, JAMA.
[28] W. März,et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. , 2010, European heart journal.
[29] L. Schurgers,et al. The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.
[30] G. Curhan,et al. Parathyroid hormone and the risk of incident hypertension , 2008, Journal of hypertension.
[31] Stefan Pilz,et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. , 2008, Archives of internal medicine.
[32] Sharon M Moe,et al. Mechanisms of vascular calcification in chronic kidney disease. , 2008, Journal of the American Society of Nephrology : JASN.
[33] F. Kronenberg,et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. , 2007, Journal of the American Society of Nephrology : JASN.
[34] Animesh Nandi,et al. Suppression of Aging in Mice by the Hormone Klotho , 2005, Science.
[35] S. Kato,et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. , 2005, The Biochemical journal.
[36] J. Sundsfjord,et al. Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[37] Tadashi Kaname,et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.
[38] K. Schlüter,et al. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. , 1992, The American journal of physiology.
[39] R. Beaglehole,et al. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. , 1990, International journal of epidemiology.
[40] S. Plein,et al. Effects of Vitamin D on Cardiac Function in Patients With Chronic HF The VINDICATE Study , 2016 .
[41] G. Yang,et al. Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD , 2014, Osteoporosis International.
[42] S. Mundra,et al. Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .